Factors associated with lithium efficacy in bipolar disorder

Harvard Review of Psychiatry

Volumn 22, Issue 6, 2014, Pages 353-357

  Rybakowski, Janusz K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

BDNF; Clinical factors; Cognitive functions; Genetics; Lithium prophylaxis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; LITHIUM DERIVATIVE; PSYCHOTROPIC AGENT;

BIPOLAR DISORDER; CIRCADIAN RHYTHM; COGNITION; COMORBIDITY; DISEASE COURSE; DISORIENTATION; DRUG EFFICACY; FAMILY HISTORY; GENETIC ASSOCIATION; GENOTYPE; HOSPITALIZATION; HUMAN; HYPOMANIA; INTRACELLULAR SIGNALING; META ANALYSIS (TOPIC); MONOTHERAPY; NERVE STIMULATION; NEUROPROTECTION; PRIORITY JOURNAL; REMISSION; REVIEW; GENETICS; PSYCHOLOGY; TEMPERAMENT; TREATMENT OUTCOME;

BIPOLAR DISORDER; HUMANS; LITHIUM COMPOUNDS; PSYCHOTROPIC DRUGS; TEMPERAMENT; TREATMENT OUTCOME;

EID: 84925787344     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000006     Document Type: Review

References (45)

1. Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;2:349-52.
2. Hartigan G. The use of lithium salts in affective disorders. Br J Psychiatry 1963;109:810-4.
3. Schou M, Thompsen K. Lithium prophylaxis of recurrent endogenous affective disorders. In: Johnson FN, ed. Lithium research and therapy. London: Academic, 1976:63-84.
4. Moncrieff J. Lithium: evidence reconsidered. Br J Psychiatry 1997;171:113-9.
5. Geddes JR, Burgess S, Kawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-22.
6. Nivoli AMA, Murru A, Vieta E. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology 2010;62:27-35.
7. Rybakowski JK. Lithium in neuropsychiatry: a 2010 update. World J Biol Psychiatry 2011;12:340-8.
8. Grof P. Excellent lithium responders: people whose lives have been changed by lithium prophylaxis. In: Birch NJ, Gallicchio VS, Becker RW, eds. Lithium: 50 years of psychopharmacology: new perspectives in biomedical and clinical research. Cheshire, CT: Weidner, 1999:36-51.
9. Rybakowski JK, Chłopocka-Wozńiak M, Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering lithium treatment in the 1970s and 1980s. Bipolar Disord 2001;3:63-7.
10. Post R. Acquired lithium resistance revisited: discontinuationinduced refractoriness versus tolerance. J Affect Disord 2012;140:6-13.
11. Beghöfer A, Alda M, Adli M, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry 2008;69:1860-8.
12. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002;63:942-7.
13. Kleindienst N, Engel RR, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005;7:404-17.
14. Grof P. Sixty years of lithium responders. Neuropsychobiology 2010;62:27-35.
15. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6th ed. Leipzig: Barth, 1899.
16. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord 2005;85:3-16.
17. Mason O, Claridge G. The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE): further description and extended norms. Schizophr Res 2006;82:203-11.
18. Rybakowski JK, Dembinska D, Kliwicki S, Akiskal KK, Akiskal HH. TEMPS-A and long-term lithium response: positive correlationwith hyperthymic temperament. J AffectDisord 2013;145:187-9.
19. Perugi G, Maremmani I, Toni C, Madaro D, Mata B, Akiskal HS. The contrasting influence on depressive and hyperthymic temperaments on psychometrically derived manic subtypes. Psychiatry Res 2001;101:249-58.
20. Goto S, Terao T, Hoaki N, Wang Y. Cyclothymic and hyperthymic temperaments may predict bipolarity in major depressive disorder: a supportive evidence for bipolar II1/2 and IV. J Affect Disord 2011;129:34-8.
21. Passmore MJ, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110-4.
22. Dembinska-Krajewska D, Kliwicki S, Chlopocka-Wozniak M, Rybakowski J. Efficacy of prophylactic lithium administration in bipolar affective illness and schizotypic traits [in Polish]. Farmakoterapia w Psychiatrii i Neurologii 2012;3-4:153-8.
23. Schurhoff F, Laguerre A, Szoke A, Meary A, Leboyer M. Schizotypal dimensions: continuity between schizophrenia and bipolar disorders. Schizophr Res 2005;80:235-42.
24. Gray JD, McEwen BS. Lithium's role in neural plasticity and its implications for mood disorders. Acta Psychiatr Scand 2013;128:347-61.
25. Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat 2013;9:493-500.
26. Quiroz JA, Machado-Vieira R, Zarate CA, Manji HK. Novel insights in lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010;62:50-60.
27. Rybakowski JK, Suwalska A, Skibinska M, et al. Prophylactic lithiumresponse and polymorphismof the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005;38:166-70.
28. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008;9:1595-603.
29. Savitz J, Van Der Merve L, Ramesar R. Personality endophenotypes for bipolar affective disorder: a family-based genetic association analysis. Genes Brain Behav 2008;7:869-76.
30. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 2007;144 B: 820-3.
31. Yazlovitskaya EM, Edwards E, Thotala D, et al. Lithium treatment prevents neurocognitive deficit resulting fromcranial irradiation. Cancer Res 2006;66:11179-86.
32. Nocjar C, Hammonds MD, Shim SS. Chronic lithium treatment magnifies learning in rats. Neuroscience 2007;150:774-88.
33. Zhang L, Chen X, Feng W, Cui Y, Xu S, Che Y. Enhancing effects of chronic lithium treatment on detour learning in chicks. Biol Trace Elem Res 2012;148:38-43.
34. Senturk V, Goker C, Bilgic A, et al. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord 2007;9(suppl 1):136-44.
35. Mora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. PsycholMed 2013;43:1187-96.
36. Rybakowski JK, Permoda-Osip A, Borkowska A. Response to prophylactic lithiumin bipolar disorder may be associated with a preservation of executive cognitive functions. Eur Neuropsychopharmacol 2009;19:791-5.
37. Rybakowski JK, Suwalska A. Excellent lithiumresponders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010;13:617-22.
38. Kapczinski F, Fernandes BS, Kauer-Sant'Anna M, et al. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatr 2009;21:272-4.
39. Zubieta JK, Huguelet P, O'Neil RL, Giordani BJ. Cognitive function in euthymic bipolar I disorder. Psychiatry Res 2001;102:9-20.
40. Cavanagh JT, Van Beck M, Muir W, Blackwood DH. Casecontrol study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry 2002;180:320-6.
41. Dickerson FB, Boronow JJ, Stallings C, et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry 2004;55:588-93.
42. Rybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991;2:43-7.
43. Rybakowski JK. Genetic influences on response to mood stabilizers in bipolar disorder. Current status of knowledge. CNS Drugs 2013;2:165-73.
44. Schulze TG, Alda M, Adli M, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010;62:72-8.
45. Schulze T. The Consortium on Lithium Genetics (ConLiGen) genome-wide association studies of lithium response phenotypes in bipolar disorder. Paper presented at the 28th CINP Congress of Neuropsychopharmacology, Stockholm, June 2012.